Table 1 Significantly mutated pathways in gastric cancer.

From: Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing

Category

Term

Count

P -Value

BH corrected

Genes

KEGG

hsa04512: ECM-receptor interaction

9

1.39E−04

1.33E−02

LAMA4, COL4A1, ITGA5, LAMA5, COL6A3, COL5A3, COL11A1, COL5A1, THBS4

BIOCARTA

h_tgfbPathway: TGF beta signaling pathway

5

2.66E−04

2.42E−02

CREBBP, TGFBR2, SMAD4, CDH1, APC

KEGG

hsa04520: Adherens junction

8

4.94E−04

2.34E−02

ERBB2, CREBBP, TGFBR2, RHOA, SMAD4, CTNND1, CDH1, CTNNA3

KEGG

hsa04360: Axon guidance

10

5.66E−04

1.80E−02

EPHA4, EPHA7, LIMK2, SEMA3E, SEMA3D, RHOA, NTNG1, SLIT2, EPHA2, EPHA3

KEGG

hsa05200: Pathways in cancer

16

8.78E−04

2.09E−02

COL4A1, STK36, ERBB2, CREBBP, TGFBR2, TP53, SMAD4, CDH1, CTNNA3, CBLB, LAMA4, CDKN1B, LAMA5, RHOA, PIK3CA, APC

KEGG

hsa04510: Focal adhesion

12

1.09E−03

2.06E−02

LAMA4, COL4A1, ITGA5, LAMA5, ERBB2, COL6A3, RHOA, PIK3CA, COL5A3, COL11A1, COL5A1, THBS4

KEGG

hsa05213: Endometrial cancer

6

2.54E−03

3.99E−02

ERBB2, TP53, PIK3CA, CDH1, CTNNA3, APC

  1. The recurrent mutated genes (N=384) were submitted to DAVID_ENREF_36 (ref. 40) for pathway enrichment analysis using KEGG, BIOCARTA and REACTOME. Enrichment P-value was estimated by a modified Fisher exact test. Only the pathways with a BH-corrected P-value of ≪0.05 are reported.
Back to article page